Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Votre recherche
Source: nct - Pays: Ireland,United Kingdom,Germany,Finland,Austria,Denmark,Belgium,Spain,Norway,Netherlands,Italy - Phase: complete
nct
MAJ Il y a 5 ans
An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)
Due to the rigor of the clinical development program of adalimumab for the indication of AS, the population of subjects with active AS that could enroll in previous phase 3 studies was limited. Therefore, it is necessary to further evaluate the use of adalimumab in a setting that mimics day-to-day clinical practice to obtain further safety and efficacy data by allowing subjects meeting the characteristics noted below to enter this study: - Subjects who failed another TNF inhibitor (etanercept, infliximab) - Subjects with advanced spinal ankylosis - Subjects with AS associated disorders (i.e., uveitis, IBD, and psoriasis)
Pays
Austria
,
Belgium
,
Denmark
,
Finland
,
France
,
Germany
,
Greece
,
Ireland
,
Italy
,
Netherlands
,
Norway
,
Spain
,
Sweden
,
Switzerland
,
United Kingdom
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
1